SGLT2 Inhibitors and Hypomagnesemia in Elderly Type 2 Diabetes Patients

A retrospective cross-sectional study of 2,827 patients aged 60 and older with Type 2 diabetes, conducted at Wenzhou Central Hospital between January 2023 and December 2024. The research investigates the correlation between SGLT2 inhibitor use and hypomagnesemia, employing multivariable logistic regression and propensity score matching analyses. The dataset includes patient-level data used to compute adjusted odds ratios for hypomagnesemia.

Use Cases

• Analyzing the association between SGLT2 inhibitor use and hypomagnesemia risk based on patient records.
• Investigating the relationship between HbA1c levels and hypomagnesemia incidence in elderly diabetic patients.
• Studying the effect of metformin administration on magnesium levels using multivariable regression models.
• Conducting propensity score matching analyses to control for confounders in observational clinical data.

Strengths

• Dataset includes 2,827 patient records with a mean age of 72.59 years, providing a substantial sample size for analysis.
• Study design employs both multivariable logistic regression and propensity score matching to account for potential confounders.
• Specific odds ratios and confidence intervals for key findings are reported, such as an OR of 0.392 for SGLT2i use and hypomagnesemia.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single hospital in Wenzhou.

Provenance

Source

Wenzhou Central Hospital

Collection Method

Retrospective cross-sectional study

Time Range

January 2023 to December 2024

Freshness

Last updated 2026-05-15 08:36:03; freshness should be verified.

Geography

Wenzhou, China